7.41
+0.01(+0.14%)
Currency In USD
| Previous Close | 7.4 |
| Open | 7.37 |
| Day High | 7.51 |
| Day Low | 7.37 |
| 52-Week High | 12.65 |
| 52-Week Low | 5.51 |
| Volume | 2.99M |
| Average Volume | 4.75M |
| Market Cap | 2.28B |
| PE | -61.75 |
| EPS | -0.12 |
| Moving Average 50 Days | 6.22 |
| Moving Average 200 Days | 8.12 |
| Change | 0.01 |
If you invested $1000 in Amicus Therapeutics, Inc. (FOLD) 10 years ago, it would be worth $454.32 as of August 18, 2025 at a share price of $7.41. Whereas If you bought $1000 worth of Amicus Therapeutics, Inc. (FOLD) shares 5 years ago, it would be worth $504.42 as of August 18, 2025 at a share price of $7.41.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025
GlobeNewswire Inc.
Jul 21, 2025 11:00 AM GMT
PRINCETON, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, July 31, 2025, at 8:30 a.m. ET to discuss financial results for t
Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan
GlobeNewswire Inc.
Jun 25, 2025 11:00 AM GMT
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in Japan for Adults with Late-onset Pompe Disease (LOPD)PRINCETON, N.J., and TOKYO, June 25, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Japa
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve
GlobeNewswire Inc.
Jun 03, 2025 11:00 AM GMT
PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL study of cipaglucosidase alfa-atga + miglustat (cip